Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same
The inventive technology includes a novel immunostimulatory RNA vaccine for the COVID-19 coronavirus. In one preferred aspect, the inventive technology includes a novel mRNA sequence encoding at least one antigenic peptide or protein comprising or consisting of a COVID-19 coronavirus protein or a fragment or variant thereof.
1 . A messenger RNA (mRNA) comprising one or more coding regions encoding at least one peptide derived from a COVID-19 coronavirus, and optionally wherein said one or more coding regions comprises one or more coding regions encoding peptide derived from a COVID-19 coronavirus, according to SEQ ID NO. 4-6, 12-15, and 17, or a fragment or variant thereof.
2 . The mRNA of claim 1 , wherein said mRNA comprises a plurality of mRNA each comprising at least one coding region, encoding at least one peptide derived from a COVID-19 coronavirus, according to SEQ ID NO. 4-6, 12-15, and 17, or a fragment or variant thereof.
3 . The mRNA of claim 1 , wherein said mRNA comprises an mRNA selected from the group consisting of: an mRNA encoded by the nucleotide sequence according to SEQ ID NO. 1-3, 16, 18-21, a nucleotide sequence having at least 95% sequence identity SEQ ID NO. 1-3, 16, 18-21, or a fragment or variant thereof.
4 . The mRNA of claim 1 , wherein said peptide derived from a COVID-19 coronavirus comprises the spike protein (S) of a COVID-19 coronavirus, or a fragment or variant thereof.
5 . The mRNA of claim 4 , wherein the spike protein (S) of a COVID-19 coronavirus is encoded by the nucleotide sequence according to SEQ ID NO. 4.
6 . The mRNA of claim 1 , wherein said peptide derived from a COVID-19 coronavirus comprises the receptor-binding motif (RBM) of 51 of a COVID-19 coronavirus, or a fragment or variant thereof.
7 . The mRNA of claim 6 , wherein the receptor-binding motif (RBM) of 51 of a COVID-19 coronavirus is encoded by the nucleotide sequence according to SEQ ID NO. 5.
8 . The mRNA of claim 1 , wherein said peptide derived from a COVID-19 coronavirus comprises the nucleocapsid protein (NCP) of a COVID-19 coronavirus, or a fragment or variant thereof.
9 . The mRNA of claim 8 , wherein the nucleocapsid protein (NCP) of a COVID-19 coronavirus is encoded by the nucleotide sequence according to SEQ ID NO. 6.
10 . The mRNA of claim 1 , wherein said peptide derived from a COVID-19 coronavirus comprises the FuPep region of the spike protein subunit 1 (51) of a COVID-19 coronavirus, or a fragment or variant thereof.
11 . The mRNA of claim 10 , wherein the FuPep region of the spike protein subunit 1 (51) of a COVID-19 coronavirus is encoded by the nucleotide sequence according to SEQ ID NO. 17.
12 . The mRNA of claim 1 , and further comprising a 5′ N7-methylguanine cap.
13 . The mRNA of claim 1 , and further comprising a 5′ untranslated region (UTR) and/or a 3′ UTR.
14 . The mRNA of claim 13 , wherein said 5′ UTR comprises a β globin 5′ UTR from Xenopus laevis , or a fragment or variant thereof, and/or 3′ UTR comprises a α globin 3′ UTR from Xenopus laevis , or a fragment or variant thereof.
15 . The mRNA of claim 14 , wherein said β globin 5′ UTR from Xenopus laevis is encoded by the nucleotide sequence according to SEQ ID NO. 7, and wherein said α globin 3′ UTR from Xenopus laevis is encoded by the nucleotide sequence according to SEQ ID NO. 8.
16 - 19 . (canceled)
20 . The mRNA of claim 1 , and further comprising at least signal coding sequence, or a fragment or variant thereof.
21 . The mRNA of claim 20 , wherein said signal coding sequence comprises an IgE signal coding sequence, or a fragment or variant thereof.
22 . The mRNA of claim 22 , wherein said IgE signal coding sequence is encoded in the nucleotide sequence according to SEQ ID NO. 9.
23 - 37 . (canceled)
38 . An isolated mRNA encoded by the nucleotide sequence selection from the group consisting of: SEQ ID NO. 1-3, 16, 18-21, a nucleotide sequence having at least 95% sequence identity SEQ ID NO. 1-3, 16, 18-21, and a fragment or variant thereof.
39 - 52 . (canceled)
53 . The mRNA of claim 1 , wherein said mRNA is suitable for use as a vaccine.
54 . The mRNA of claim 38 , wherein said mRNA is suitable for use as a vaccine.